Clinical trials: Huntington's Disease (HD)
Huntington's Disease (HD)
Facilitating Effective Eating With DoddleBags: A Single-Arm Acceptability Study Of DoddleBags to Assess Impact on Self Feeding Behaviours in a Huntington's Disease Population
Primary Objectives To assess the acceptability of using the DoddleBags feeding aid in people with HD, by using a food diary to track food intake and using semi-structured interviews to ask questions about how easy or difficult it…
- Trial name
- FEEDhd (NCT07299682)
- Testing
- DoddleBags
- Where
- 7 sites in United Kingdom
- Sponsor
- University of Hull
Huntington Disease
Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
Positron Emission Tomography (PET) is a functional imaging technique, which enables in vivo visualization of biological molecules expressed in human tissues.
- Trial name
- NCT05360082
- Testing
- [11C]UCB-J PET, [18F]SynVest-1 PET
- Where
- Belgium
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Huntington Disease
Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease
Cellavita HD is a stem-cell therapy for Huntington's Disease. This is a first-in-human, non-randomized, phase I study in which participants with Huntington's Disease will receive three intravenous injections and will be followed…
- Trial name
- SAVE-DH (NCT02728115)
- Testing
- Cellavita HD Lower Dose, Cellavita HD Higher dose
- Where
- Brazil
- Volunteers
- 6 people
- Sponsor
- Azidus Brasil
Huntington's Disease
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
The purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (HD).
- Trial name
- Open PRIDE-HD (NCT02494778)
- Testing
- Pridopidine
- Where
- 46 sites in United States, Australia and 9 more
- Volunteers
- 248 people
- Sponsor
- Prilenia
Huntington's Disease
Deep Brain Stimulation of the Globus Pallidus in Huntington's Disease
This is a single centre, controlled phase I study, which evaluates safety and efficacy of stimulation of lower caudal two contacts (GPI) vs. upper cranial two contacts (GPE) in Huntington´s disease (HD).
- Trial name
- NCT00902889
- Testing
- Stimulation
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Huntington's Chorea
Efficacy and Safety of SOM3355 in Huntington's Disease Chorea
Phase IIa study to evaluate the efficacy and safety of SOM3355 in chorea movements associated with Huntington's disease
- Trial name
- NCT03575676
- Testing
- SOM3355 100mg BID, SOM3355 200mg BID
- Where
- 4 sites in Spain
- Volunteers
- 32 people
- Sponsor
- SOM Innovation Biotech SA
Huntington Disease
Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD)
The aim of the study is to prove the efficacy and safety of pallidal DBS in HD patients and to show superiority of DBS on motor function in the stimulation group compared to stimulation-off group
- Trial name
- HD-DBS (NCT02535884)
- Testing
- ACTIVA® PC neurostimulator (Model 37601)
- Where
- 12 sites in Austria, France and 2 more
- Volunteers
- 48 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Huntington Disease
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
The primary goal of this study is to evaluate the long-term safety and pharmacodynamic effects of votoplam in participants with HD.
- Trial name
- NCT06254482
- Testing
- Votoplam
- Where
- 24 sites in Australia, Austria and 8 more
- Volunteers
- 144 people
- Sponsor
- Novartis Pharmaceuticals
Huntington Disease
A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease
The purpose of this study is to determine if Dimebon is safe and effective for the treatment of cognitive impairment in Huntington disease.
- Trial name
- HORIZON (NCT00920946)
- Testing
- Dimebon
- Where
- 37 sites in United States, Australia and 5 more
- Volunteers
- 403 people
- Sponsor
- Medivation, Inc.
Huntington Disease
Making HD Voices Heard
The Pilot Study, Making HD Voices Heard, will ask people living with HD to report what they experience and how they function.
- Trial name
- NCT05268029
- Where
- United States
- Volunteers
- 698 people
- Sponsor
- Huntington Study Group
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's…
- Conditions
- Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
- Trial name
- NCT05822908
- Testing
- VO659
- Where
- 14 sites in Denmark, France and 4 more
- Volunteers
- 68 people
- Sponsor
- Vico Therapeutics B. V.
Huntington Disease
Family Health After Predictive Huntington Disease (HD) Testing
The purpose of this study is to identify health management concerns and needs of family members of asymptomatic and symptomatic persons with mutation in the gene for Huntington Disease (HD).
- Trial name
- NCT00075140
- Testing
- Mutation in the gene
- Where
- United States
- Volunteers
- 422 people
- Sponsor
- National Institute of Nursing Research (NINR)
Huntington Disease
Transcranial Static Magnetic Stimulation (tSMS) in Huntington's Disease (HD)
Huntington's disease (HD) is a neurodegenerative pathology characterized by choreic hyperkinesias which represent the typical motor symptom and are represented by involuntary, aimless, irregular, recurrent, unpredictable and…
- Trial name
- NCT06976983
- Testing
- Portable ergonomic helmet for real tSMS
- Volunteers
- 30 people
- Sponsor
- Neuromed IRCCS
Huntington Disease
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
This study is designed to determine the effect of 2 gram/day of ethyl-EPA on motor (movement) signs and symptoms of Huntington disease.
- Trial name
- NCT00146211
- Testing
- Ethyl-EPA (Miraxion™)
- Where
- 41 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Amarin Neuroscience Ltd
Huntington Disease
Project AWARE 2.0 to Improve Awareness, Willingness and Ability for Research and Enrollment in Clinical Research
The Project AWARE 2.0 Survey is intended to gain knowledge about the feelings, attitudes, and beliefs of HD family members, care partners and others affected by HD towards the way drug trials and observational studies are…
- Trial name
- NCT06343220
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Huntington Study Group
Huntington Disease
Impact of Apathy on Caregiving in HD. Version 1
Huntington's disease (HD) can affect motivation. People with HD may not wash often, keep their house clean and tidy, or eating healthy food.
- Trial name
- NCT05913154
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of East Anglia
Huntington Disease
Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)
Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances.
- Trial name
- NCT00675077
- Testing
- Far Infrared Radiation
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- GAAD Medical Research Institute Inc.
Huntington's Disease, Chorea
Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China
The Primary Objective: To evaluate the real-world effectiveness of deutetrabenazine in adult participants with chorea associated with Huntington's disease in China.
- Trial name
- NCT07601516
- Testing
- Deutetrabenazine
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Early Manifest Huntington Disease
A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease
This is the first study of branaplam in adults with Huntington's Disease (HD) to determine the correct dose required to lower mutant huntingtin protein (mHTT) levels in the cerebrospinal fluid (CSF) to a degree expected to be…
- Trial name
- VIBRANT-HD (NCT05111249)
- Testing
- Branaplam
- Where
- 12 sites in Canada, France and 3 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Huntington Disease
Natural History Study in Huntington Disease Gene Expansion Carriers (HDGECs) - SHIELD HD
SHIELD HD is an international, multisite, prospective, longitudinal cohort natural history study to assess the natural history of HD and its biomarkers that are associated with modulation of the number of cytosine-adenine-guanine…
- Trial name
- SHIELD HD (NCT04406636)
- Where
- 10 sites in United States, Canada and 3 more
- Volunteers
- 70 people
- Sponsor
- CHDI Foundation, Inc.